RetiredUnitedHealthcarePolicy CS081LA.L

During Radical Prostatectomy (for Louisiana Only)

Policy governing the medical necessity and coverage stance for autologous or allogenic nerve graft procedures to restore erectile function during or after radical prostatectomy for members in Louisiana.

Policy Summary

PayerUnitedHealthcare

PolicyDuring Radical Prostatectomy (for Louisiana Only)

Policy CodePolicy CS081LA.L

Change TypeRetiredsupporting information updated

Effective DateFeb 1, 2026

Next Review DateN/A

Key ActionDo not submit prior authorization to request coverage for nerve grafting to restore erectile function; the procedure is designated not medically necessary under this Louisiana policy.

SourceLink

POLICY UPDATE CHANGES

Policy retired; Louisiana plan membership disenrolled on Apr. 1, 2026.

Supporting sections (Description of Services, Clinical Evidence, FDA, References) were updated to reflect current information as of Feb 1, 2026.

Retired policy; Louisiana plan membership disenrolled on Apr. 1, 2026.

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

Louisiana-onlyjurisdiction

Not medically necessarycoverage stance

Apr 1, 2026retirement date

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Updated 02/01/2026last update

RCT stopped early (n=107)key trial

Coverage Criteria

Not Medically Necessary

Not medically necessary when proposed to restore erectile function during or after radical prostatectomy

Primary coverage determination: Autologous (e.g., sural) or allogenic nerve grafts to restore erectile function during or after radical prostatectomy are unproven and not medically necessary due to insufficient evidence of efficacy.

Supported by randomized and observational evidence summarized in Clinical Evidence and NCCN guidance.

Clinical guidance indicates that recovery of erectile function after radical prostatectomy is strongly linked to the extent of cavernous nerve preservation, the patient’s age at surgery, and preoperative erectile function. Nerve-sparing techniques have been associated with improvements in urinary and sexual function, whereas attempts to replace resected nerves with grafts have not shown effectiveness when wide resection of the neurovascular bundles is performed. The policy therefore characterizes autologous (e.g., sural) and allogenic nerve grafting to restore erectile function during or after radical prostatectomy as unproven and not medically necessary due to insufficient evidence of efficacy.

This policy has been retired for Louisiana members; Louisiana plan membership was disenrolled effective 04/01/2026.

Autologous (for example, sural) or allogenic nerve grafts proposed to restore erectile function during or after radical prostatectomy are regarded as unproven and are considered not medically necessary because current evidence does not demonstrate sufficient efficacy.

Applicable Codes

Applicable Codes (reference only)CPT

55899	Unlisted procedure, male genital system.
64999	Unlisted procedure, nervous system

Provider Actions and Operational Notes

Denial Risk

Prior authorization stance

Prior authorization will not make an otherwise non-covered or investigational service a covered benefit. Requests for nerve grafting for restoration of erectile function are likely to be denied when the service is considered unproven or not medically necessary under this policy.

Note

Verify plan-specific coverage requirements

Benefit coverage is governed by the member's specific plan and may be subject to federal, state, or contractual mandates. Always verify plan-specific coverage requirements and any applicable mandates before rendering services or submitting claims.

Check the member's evidence of coverage/benefit booklet for exclusions or mandates.
Consult state-specific mandates (e.g., Louisiana plan rules) and any federal requirements that may supersede plan policy.

Denial Risk

Background

Erectile dysfunction commonly follows radical prostatectomy, particularly when neurovascular bundles are resected. Preservation of the cavernous nerves (nerve-sparing surgery) is a key determinant of postoperative erectile function recovery, along with patient age and baseline erectile function. Although surgical techniques such as cavernous nerve reconstruction and nerve grafting (including sural nerve grafting and experimental conduits) have been explored to restore function, the available evidence does not establish that grafting reliably restores erectile function, especially when wide neurovascular bundle resection is necessary.

Definitions

Sural nerve grafting (SNG)

DefinitionHarvesting a segment of the sural nerve from the lower leg (a nerve traveling along the short saphenous vein) and grafting it to the resected cavernous nerve during radical prostatectomy to attempt restoration of erectile function.

Technique detailsDonor nerve (sural) is considered expendable and is joined to the distal and proximal ends of the resected cavernous nerve; grafting may be performed on one or both sides.

Common donor nervesSural nerve (most common); other donors described include genitofemoral nerve in the literature.

PurposeIntended to bridge resected cavernous nerves during radical retropubic prostatectomy to increase likelihood of restoring spontaneous erectile function.

Spider silk nerve reconstruction (SSNR)

Definition

Revision History

2026-04-01retirementLatest

Policy retired and Louisiana plan membership disenrolled effective April 1, 2026.

2026-02-01supporting_information_update

Supporting information updated (Description of Services, Clinical Evidence, FDA, References); previous version archived.

Policy Summary

PayerUnitedHealthcare

PolicyDuring Radical Prostatectomy (for Louisiana Only)

Policy CodePolicy CS081LA.L

Change TypeRetiredsupporting information updated

Effective DateFeb 1, 2026

Next Review DateN/A

Key ActionDo not submit prior authorization to request coverage for nerve grafting to restore erectile function; the procedure is designated not medically necessary under this Louisiana policy.

SourceLink

On This Page

Denial risk for nerve grafting

Replacement of resected cavernous nerves with nerve grafts for erectile function recovery is considered unproven. Expect a high likelihood of denial when nerve grafting is requested for this indication.

Note

Clinical considerations prior to surgical interventions

Clinical considerations prior to surgical intervention: recovery of erectile function after radical prostatectomy is linked to degree of cavernous nerve preservation, patient age, and preoperative erectile function. Nerve-sparing techniques improve outcomes; grafting is unlikely to help when wide neurovascular bundle resection has occurred.

Assess preoperative erectile function and candidacy for nerve-sparing approaches before considering grafting.
Discuss with patient that donor nerve harvest (e.g., sural nerve) carries morbidity and may not improve erectile outcomes if cavernous nerves were widely resected.
Consider alternative management (phosphodiesterase inhibitors, vacuum devices, intracavernosal injections, penile prosthesis) when nerve preservation is not achievable.

Note

Coverage decisions must reference federal/state/contractual requirements

Providers should check applicable federal, state, and contractual requirements when applying this policy. In the event of a conflict between this policy and governing legal or contractual requirements, the federal/state/contractual requirements prevail.

Note

Provider reminder and supplemental note

Supplemental provider note: This policy is informational and not medical advice. UnitedHealthcare may use external tools (e.g., InterQual) to assist in benefit administration; confirm any utilization management requirements (prior authorization, medical necessity criteria) with plan-specific processes.

Confirm whether prior authorization or other utilization review is required for nerve procedures under the member's plan.
Document clinical rationale and prior conservative therapies when submitting requests for surgical interventions.

Billing Rule

Coding reference

Coding reference: listed procedure codes are provided for reference only and do not indicate coverage. Inclusion does not guarantee reimbursement.

CPT 55899 — Unlisted procedure, male genital system
CPT 64999 — Unlisted procedure, nervous system

Use of a spider silk conduit (major-ampullate dragline from Nephila edulis) laid across dissected neurovascular bundle sites to promote nerve regeneration; tested in small feasibility series.

Intended usePlaced across sites of dissected neurovascular bundles during or after prostate surgery to encourage nerve regrowth for erectile function recovery.

Evidence contextReported in small feasibility series and emerging technique reviews; included among novel surgical approaches in systematic reviews.

Cavernous nerve reconstruction / nerve grafting

DefinitionSurgical techniques for reconstruction of the cavernous nerves or interposition of nerve grafts to restore erectile function after radical prostatectomy.

Procedure descriptionReplacement of resected cavernous nerves with interposed donor nerve segments (autologous or allogenic) joined to proximal and distal nerve ends to attempt functional recovery.

Clinical contextDeveloped because erectile dysfunction commonly occurs after bilateral resection of neurovascular bundles during radical prostatectomy; nerve-sparing surgery is not always feasible.

Evidence summaryDescribed in case series and reports with variable outcomes; referenced in reviews and small outcome studies but considered unproven for routine restoration of erectile function.